Maravai LifeSciences Forecast, price target & analysts
Maravai LifeSciences Target price 2025 - Analyst rating & recommendation
Maravai LifeSciences Classifications & Recommendation:
Maravai LifeSciences Price Target
| Target Price | $8.43 |
| Price | $3.05 |
| Potential |
176.45%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Maravai LifeSciences 2026 .
The average Maravai LifeSciences target price is $8.43.
This is
176.45%
register free of charge
$12.00
293.44%
register free of charge
$3.00
1.64%
register free of charge
|
|
| A rating was issued by 15 analysts: 7 Analysts recommend Maravai LifeSciences to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2026 of
176.45%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 288.95 | 260.15 |
| 67.28% | 9.97% | |
| EBITDA Margin | 15.43% | 16.87% |
| 78.16% | 9.34% | |
| Net Margin | -44.10% | -43.99% |
| 264.69% | 0.25% |
15 Analysts have issued a sales forecast Maravai LifeSciences 2024 . The average Maravai LifeSciences sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Maravai LifeSciences EBITDA forecast 2024. The average Maravai LifeSciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Maravai LifeSciences Analysts have issued a net profit forecast 2024. The average Maravai LifeSciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.90 | -0.81 |
| 153.89% | 10.00% | |
| P/E | negative | |
| EV/Sales | 2.63 |
6 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Maravai LifeSciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Maravai LifeSciences...
Current Maravai LifeSciences Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird | Locked ➜ Locked | Locked | Feb 26 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Dec 05 2024 |
| Wolfe Research | Locked ➜ Locked | Locked | Nov 14 2024 |
| Baird | Locked ➜ Locked | Locked | Nov 08 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Nov 08 2024 |
| William Blair | Locked ➜ Locked | Locked | Nov 08 2024 |
| Goldman Sachs | Locked ➜ Locked | Locked | Oct 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Dec 05 2024 |
|
Locked
Wolfe Research: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
Baird: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
William Blair: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Oct 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
